The 20-Year Industry Secret: Redefining Neurodegenerative Treatment

In this episode of Power to the Patients, Brandon Li sits down with Dr. Gabriel Vargas, Chief Medical Officer at CuraSen Therapeutics, to explore how targeting the adrenergic system could offer both symptomatic relief and disease-modifying potential for Alzheimer's, Parkinson's, and depression. From his two decades developing breakthrough therapies in neurology and psychiatry, including the migraine treatment Erenumab, Dr. Vargas breaks down translational medicine, challenges the amyloid hypothesis, and reveals why shorter clinical trials may be missing the bigger picture.